Press Releases

ANN ARBOR – Eric Baude, Ph.D., an attorney in the Ann Arbor office of Brinks Hofer Gilson & Lione, one of the largest intellectual property law firms in the U.S., was a contributor to the recently published book entitled, Biomarkers in Drug Development: A Handbook of Practice, Application and Strategy, by Michael R. Bleavins (Editor), Claudio Carini (Editor), Mallé Jurima-Romet (Editor), and Ramin Rahbari (Editor).

Dr. Baude co-authored the section entitled, "Biomarker Patent Strategies: Opportunities and Risks," as part of the book’s exploration of the practical aspects of biomarker implementation. Biomarkers in Drug Development: A Handbook of Practice, Application and Strategy, is available for purchase at www.wiley.com.

At Brinks, Dr. Baude focuses on patent law and related matters, particularly in the fields of biotechnology, pharmaceuticals and chemistry. His practice involves patent application drafting and prosecution, patent portfolio management, patent due diligence analyses, freedom-to-operate analyses, invalidity/non-infringement opinions and licensing activities.

Prior to joining Brinks, Dr. Baude was an in-house patent attorney for Pfizer Inc. He provided business-focused patent counsel to scientists, development teams and business managers. At Pfizer he was involved in creating global patent portfolios around small molecule and large protein therapeutics for a variety of indications including inflammation, CNS conditions, bacterial infections and dermatology. Dr. Baude has carried out freedom-to-operate analyses of recombinant DNA and protein patents, chemical compound patents and chemical synthesis patents. He has experience in advising Latin American managers on product patent issues. He also spent time in Japan, providing patent services to the local R&D facility on a short-term assignment.

Prior to Pfizer, Dr. Baude was an associate in an intellectual property law firm in San Francisco. He represented a range of clients, including government and academic institutions, research tool companies, start-up companies and pharmaceutical companies. He prepared and prosecuted patents for small organic molecules, therapeutic proteins, peptides, DNA, biological assays, cell lines, adjuvants and antibodies.

Dr. Baude holds a Ph.D. in Biological Chemistry from the University of Michigan, a J.D. with honors from the Illinois Institute of Technology, Chicago-Kent College of Law and a B.S. in Biochemistry from the University of Minnesota. He is a resident of Ann Arbor.

Founded in 1917, Brinks Hofer Gilson & Lione is based in Chicago with five additional offices across the country, including Ann Arbor, serving the intellectual property needs of clients from around the world. The firm is one of the largest IP law firms in the country, with more than 180 attorneys, scientific advisors and patent agents specializing in intellectual property litigation and all aspects of patent, trademark, copyright, trade secret, unfair competition, intellectual asset management, and technology and licensing agreements. Brinks routinely handles assignments in fields as diverse as electrical, chemical, mechanical, biotechnology, pharmaceutical, nanotechnology, Internet and computer technology, as well as in trademarks and brand names for a wide variety of products and services.